# Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

> **NCT07751042** · PHASE1,PHASE2 · RECRUITING · sponsor: **Strand Therapeutics Inc.** · enrollment: 220 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **BIOLOGICAL:** STX-003
- **BIOLOGICAL:** KEYTRUDA®

## Key facts

- **NCT ID:** NCT07751042
- **Lead sponsor:** Strand Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2030-07-17
- **Final completion:** 2030-11-15
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07751042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07751042, "Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07751042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*